| Purpose | AGM Date | Announcement Date |
|---|---|---|
| AGM | 23 Jul 2025 | 23 Apr 2025 |
| Approved convening of the 32nd Annual General Meeting of the Company on Wednesday, July 23, 2025. Copy of the notice convening the Annual General Meeting will be sent in due course. Notice of 32nd Annual General Meeting (AGM) scheduled on Wednesday, July 23, 2025 (As Per BSE Announcement Dated on: 28/06/2025) Proceedings of the 32nd Annual General Meeting (As Per BSE Announcement Dated on :23.07.2025) We are enclosing herewith the scrutinizers report and voting result with respect to 32nd AGM of the Company held on July 23, 2025. (As Per BSE Announcement Dated on :24.07.2025) | ||
The outcome of the inspection has been classified as “Voluntary Action Indicated” or VAI.
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
